1. Diabetic foot ulcer in the Western Pacific Region: Current data on ulceration rates and microbial profiles, gaps and charting strategies.
- Author
-
Lim QH, Loy LC, Abdul Hadi H, Faheem NAN, Shaharuddin IS, Sri La Ponnampalavanar S, and Lim LL
- Abstract
The Western Pacific Region hosts the largest proportion of people with diabetes. Despite being a key diabetes-related complication, diabetic foot ulcer has been neglected in both prevention and treatment efforts. This narrative review highlights available data on the burden (either prevalence or incidence), as well as microbial profiles of diabetic foot ulcers in the Western Pacific Region, identifies data gaps, and discusses strategies to address these gaps. There are substantial gaps in epidemiological data and microbial profiles for many countries in the Western Pacific Region. Addressing these gaps require developing and strengthening data collection systems for effective surveillance and benchmarking of diabetes care., Competing Interests: Conflict of interest Conflict of interest: QHL: Speaker fees from AstraZeneca, GSK, Novo Nordisk, ZP Therapeutics; SSLSP: Research grants from Pfizer and Shinogi, speaker fees from 3 M, B. Braun Medical Industry, bioMérieux, Pfizer, Shionogi, MSD, Sanofi, Johnson & Johnson; LLL: Research grants from Abbott, AstraZeneca, Boehringer Ingelheim, Novartis, ZP Therapeutics, advisory board panel for AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Servier, Viatris, ZP Therapeutics, speaker fees from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Merck, Novartis, Novo Nordisk, Roche Diabetes Care, Viatris, ZP Therapeutics; LCWL, HAH, NANF, ISS: No interests to declare., (Copyright © 2025 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2025
- Full Text
- View/download PDF